Results 141 to 150 of about 3,280,665 (275)

Botulinum Toxin for First Bite Syndrome: A Symptom‐Guided “Follow‐The‐Pain” Injection Strategy

open access: yesHead &Neck, EarlyView.
ABSTRACT Background To evaluate botulinum toxin type A (BoNT‐A) for First Bite Syndrome (FBS) and assess a symptom‐guided “Follow‐the‐Pain” (FTP) injection strategy in patients with incomplete response to standard treatment. Methods Consecutive patients with postoperative FBS were treated with ultrasound‐guided intraparotid BoNT‐A injection.
Rosario Marchese‐Ragona   +5 more
wiley   +1 more source

Pretreatment Cachexia Index Is Associated With Severe Treatment Toxicity and Overall Survival in HPV‐Negative Head and Neck Squamous Cell Carcinoma

open access: yesHead &Neck, EarlyView.
ABSTRACT Introduction Cancer cachexia is characterized by skeletal muscle loss, poor nutrition, and systemic inflammation and is common in head and neck cancer. We evaluated whether the Cachexia Index (CXI) predicts treatment toxicity and survival in HPV‐negative HNSCC.
Gianluca Savoia   +11 more
wiley   +1 more source

Assessment of Cancer‐Related Cognitive Impairments Across Anti‐Cancer Therapies in a Predominantly Breast Cancer Cohort

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Cancer survivors frequently experience cancer‐related cognitive impairment (CRCI), but the contributions of different anti‐cancer therapies remain unclear. Patients with breast or gynaecological cancer were recruited before any anti‐cancer treatment.
Qiqi Lei   +5 more
wiley   +1 more source

Patient reported outcomes and results of endometrial balloon ablation for the treatment of heavy menstrual bleeding: A single center observational cohort study

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective Heavy menstrual bleeding is one of the most common gynecologic disorders among women of reproductive age and has a significant impact on their physical, psychological, and social well‐being. Although international guidelines recommend medical therapy as the first‐line treatment, it may prove ineffective, poorly tolerated, or ...
Jonas Rudaitis   +3 more
wiley   +1 more source

Menopause hormone therapy in women with cardiovascular risk factors or established ischemic heart disease: A joint FIGO and WHF position paper

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Integrated approach to menopausal hormone therapy in women with cardiovascular risk factors or established ischemic heart disease, from early treatment initiation and risk stratification to individualized therapy, multidisciplinary follow‐up, and health‐system recommendations.
Chiara Benedetto   +9 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

open access: yesThe Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth   +10 more
wiley   +1 more source

Human biomarker navigator

open access: yesiMeta, EarlyView.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li   +29 more
wiley   +1 more source

Home - About - Disclaimer - Privacy